Abstract:Background: Irinotecan (CPT-11) has demonstrated its potent efficacy in treating various malignancies, including advanced gastrointestinal cancers as a single agent, or in combination with chemotherapeutic and targeted agents. Yet, various degrees of dose-limiting toxicities, including diarrhea and neutropenia, were observed in some patients. It was reported that the incidence of such irinotecan-related adverse events was associated with polymorphism of the uridine diphosphate glucuronosyltransferases (UGTs) gene, and demonstrated an obvious ethnic diversity. Detection of these polymorphisms may guide the clinical decision for irinotecan dosage and the chemotherapeutic partner for individualized regimens. The aim of this study is to observe the frequency and severity of various adverse events in Han patients with advanced gastrointestinal cancer who were treated with irinotecan-based therapy. Simultaneously, the relationship between severe adverse events and the UGT1A1 gene promoter polymorphism (UGT1A1*28) was investigated. Methods: Sixty-six patients (42 men and 24 women; median age, 58 years; range, 30 –7 6 years) with advanced gastrointestinal carcinoma receiving irinotecan-based chemotherapy were enrolled. The inclusive criteria were: (1) pathologically/cytologically confirmed adenocarcinoma of the gastrointestinal tract, (2) expected survival time over 3 months, (3) no severe concomitant diseases of any vital organs, (4) no jaundice and digestive tract obstruction, (5) no acute infection. The adverse events during the course of chemotherapy, the pretreatment serum bilirubin level, as well as the time to grade 3 –4 toxicities were recorded. Genomic DNA was extracted from the peripheral blood to detect the polymorphism of UGT1A1*28 (TATA box thymine-adenine TA repeats). The relationship between the severity of adverse events and the UGT1A1*28 polymorphism, pretreatment bilirubin level, as well as the time to severe toxicity was investigated. Results: Of 66 enrolled patients, 55 patients (83.3%) were identified with the thymine-adenine (TA)6/(TA)6 genotype, and 11 patients (16.7%) were identified with the thymine-adenine (TA)6/(TA)7 genotype; no (TA)7/(TA)7 genotype was found. Twenty-six of the (TA)6/(TA)6 and 5 of the (TA)6/(TA)7 patients (47.3% vs 45.5%, P ¼ 1.000) developed grade 3 – 4 neutropenia, while 5 and 4 patients (9.1% vs 36.4%, P ¼ .036) experienced grade 3 – 4 diarrhea. The occurrence of grade 3 –4 diarrhea, but not neutropenia, was closely related with the (TA)6/(TA)7 genotype in the UGT1A1 promoter region in patients receiving irinotecanbased chemotherapy. The median time to severe toxicity of these 2 groups were 9 weeks (6 cycles) and 3 weeks (2 cycles), respectively (P ¼ .186). The pretreatment serum bilirubin levels in these 2 groups were (15.1+ 1.1) mmol/L and (20.8+ 5.1) mmol/L, respectively, which were not significantly associated with the occurrence of grade 3 – 4 diarrhea and neutropenia (P ¼ .09). Conclusion: The frequency of the UGT1A1*28 gene polymorphism in Han patients is 16.7%, which is lower than that reported in Western populations. The marked increase in grade 3 –4 diarrhea is related with the (TA)6/ (TA)7 genotype of UGT1A1 in patients receiving irinotecanbased chemotherapy. Detection of this gene polymorphism might help to select optional dosage and chemo-partner of irinotecan-based regimen in treating GI cancer patients in China.

Relationship between UGT1A16/28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens

[Polymorphisms of UGT1A Gene and Irinotecan Toxicity in Chinese Colorectal Cancer Patients].

UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer.

Relationship between UGT1A1 gene polymorphisms and toxicity of irinotecan-based chemotherapy ;in colorectal cancer

Associations Between Ugt1a16/28 Polymorphisms and Irinotecan-Induced Severe Toxicity in Chinese Gastric or Esophageal Cancer Patients

Distribution of Uridine Diphosphate Glucuronosyltransferase 1A Polymorphisms and Their Role in Irinotecan-Induced Toxicity in Patients with Cancer.

UGT1A1 Predicts Outcome in Colorectal Cancer Treated with Irinotecan and Fluorouracil.

Relationship between UGT1A16/28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

Clinical Significance of UGT 1 A 1 Gene Polymorphisms on Irinotecan-Based Regimens As the Treatment in Metastatic Colorectal Cancer

OVERALL ABSTRACT WINNER (CLINICAL OUTCOMES)

UGT1A1 6/28 Polymorphisms Could Predict Irinotecan-Induced Severe Neutropenia Not Diarrhea in Chinese Colorectal Cancer Patients.

Predictive Value of UGT1A1*28 Polymorphism in Irinotecan-based Chemotherapy

A study on the relationship between the adverse events of irinotecan-based chemotherapy and UGT1A1*28 gene polymorphism

UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis

Study of Irinotecan-Induced Toxicity and Its Correlation to UGT1A1~*28 Gene Promoter Polymorphisms

UGT1A1*28 Polymorphism Predicts Irinotecan-Induced Severe Toxicities Without Affecting Treatment Outcome and Survival in Patients with Metastatic Colorectal Carcinoma.

UGT1A16, UGT1A73 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.

Clinical Study of the Correlation between UGT1A1 Polymorphism and the Safety and Efficacy of Irinotecan

Correlation Between UGT1A1 Gene Polymorphisms and Toxicity and Efficacy in Patients with Metastatic Colorectal Cancer Treated with Irinotecan Based Chemotherapy

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer

UGT1A1*6 Polymorphisms Are Correlated with Irinotecan-Induced Toxicity: a System Review and Meta-Analysis in Asians

Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens